Revisiting the biological roles of PAI2 (SERPINB2) in cancer

被引:157
作者
Croucher, David R. [2 ]
Saunders, Darren N. [3 ,4 ]
Lobov, Sergei [1 ]
Ranson, Marie [1 ]
机构
[1] Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia
[2] Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia
[3] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1L3, Canada
[4] British Columbia Canc Res Ctr, Mol Oncol & Breast Canc Program, Vancouver, BC V5Z 1L3, Canada
关键词
D O I
10.1038/nrc2400
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumour expression of the urokinase plasminogen activator correlates with invasive capacity. Consequently, inhibition of this serine protease by physiological inhibitors should decrease invasion and metastasis. However, of the two main urokinase inhibitors, high tumour levels of the type 1 inhibitor actually promote tumour progression, whereas high levels of the type 2 inhibitor decrease tumour growth and metastasis. We propose that the basis of this apparently paradoxical action of two similar serine protease inhibitors lies in key structural differences controlling interactions with components of the extracellular matrix and endocytosis-signalling co-receptors.
引用
收藏
页码:535 / 545
页数:11
相关论文
共 165 条
[1]  
Abe J, 1999, CANCER-AM CANCER SOC, V86, P2602, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2602::AID-CNCR4>3.0.CO
[2]  
2-S
[3]   MECHANISMS CONTRIBUTING TO THE CONFORMATIONAL AND FUNCTIONAL FLEXIBILITY OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 [J].
AERTGEERTS, K ;
DEBONDT, HL ;
DERANTER, CJ ;
DECLERCK, PJ .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (10) :891-897
[4]   Pivotal role of plasminogen-activator inhibitor 1 in vascular disease [J].
Agirbasli, M .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (01) :102-106
[5]   Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines [J].
Al-Ejeh, F ;
Croucher, D ;
Ranson, M .
EXPERIMENTAL CELL RESEARCH, 2004, 297 (01) :259-271
[6]   Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions [J].
Alemán, C ;
Alegre, J ;
Monasterio, J ;
Segura, RM ;
Armadans, L ;
Anglés, A ;
Varela, E ;
Ruiz, E ;
De Sevilla, TF .
CLINICAL SCIENCE, 2003, 105 (05) :601-607
[7]   Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2 [J].
Allen, BJ ;
Tian, Z ;
Rizvi, SMA ;
Li, Y ;
Ranson, M .
BRITISH JOURNAL OF CANCER, 2003, 88 (06) :944-950
[8]   In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers [J].
Allen, BJ ;
Rizvi, S ;
Li, Y ;
Tian, Z ;
Ranson, M .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 39 (1-2) :139-146
[9]   THE VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR MEDIATES THE CELLULAR CATABOLISM OF LIPOPROTEIN-LIPASE AND UROKINASE-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-I COMPLEXES [J].
ARGRAVES, KM ;
BATTEY, FD ;
MACCALMAN, CD ;
MCCRAE, KR ;
GAFVELS, M ;
KOZARSKY, KF ;
CHAPPELL, DA ;
STRAUSS, JF ;
STRICKLAND, DK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (44) :26550-26557
[10]   Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy [J].
Åstedt, B ;
Lindoff, C ;
Lecander, I .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1998, 24 (05) :431-435